Standards; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
BCX 4430 is an antiviral drug, an adenosine analog). It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease.
?您的位置：
